Transcription
Nitai Hanani 0:08
Hi, it's a great opportunity to be here. Sorry about my sore throat, apparently have been talking too much already by now. Hospitals have some very unlucky frequent fliers, the fluid overloaded heartflow patients. These patients literally breathe inside an ocean and live in misery and require frequent admissions for acute treatments that just don't solve their chronic condition. Only turning to a co founder of Paragate Medical and Paragate is set to break this vicious cycle by offering an out of hospital treatment option to help the lives of so many patients. Did you know that nine out of 10 heart failure admissions are due to fluid overload. In fact, a quarter of the repeated admissions occur within less than 30 days from the previous episode. And they cost alone more than half of the direct costs. And 30% of the patients do not respond to the direct medication so they keep coming again. And again, for acute and more aggressive treatments that carry burden complication, huge costs, it costs up to $2,000 to remove one litre of fuid from the body. But most importantly, they don't prevent the recurrence of the congestion. So imagine if you have an implantable device that works 24/7 non aggressively, continuously to actively prevent the accumulation while patients are at home. And this is what we do by removing from the body, one bottle of beer a day. But everyday. It's a fully implantable device acting as a mechanical bypass of the kidneys. By induction of controlled locking protocol. The device located in the abdominal cavity absorbs systemic isotonic fluid, with electrolytes with toxins from all over the body and drink them through a catheter into the bladder. It's a direct mechanical principle that works independently of the kidneys, and has and has no interface with the circulation or the heart. So the patient can stay at home be continuously treated, while also being monitored as the sense data. As the sense data is submitted, transmitted to the physician management platform that allows the physician to titrate the therapy per need. The laparoscopic compatible device allows a simple and safe procedure where it takes few minutes to deploy the device into the abdominal cavity and then connect it to the pump and the drainage catheter which we see now. And here's how it looks in our first in human clinical feasibility trial with our Gen one system that is currently ongoing in Poland and Georgia. So such solution affects all stakeholders, physicians and hospitals struggling nowadays to stabilize these patients could clear up beds and increase their turnover per bed, while also harnessing those patients to their own management programs. These are their patients for now. The payers benefit of the reduced readmission, where potential savings can reach $100,000 per patient, enabling them the parents to reach breakeven within a few months from the implantation itself. And we plan a dual revenue stream with direct sale to the hospitals to the care providers in estimated premium price of a $30,000. In addition to the services platform service fee for the management platform. The market comprises addressable market is 16% of the Heartfilia population. These are the events and the wet patients. And with 200,000 new incidents in Europe and the US together. The serviceable market yields 6 billion annually. The more continuous the treatment, the better the outcome is. And target is the only one to work on a truly chronic, fully implantable device without interfacing the circulation or touching the heart without external tubing and the risk of infection and without the need to apply cumbersome chemical analysis. From broader perspective, in one device, we capture three of the new therapeutic approaches to chronic heart failure A patient management, pressure reduction or decompression, and the blue ocean of the volume, the congestion. And we believe that for most big players to try to build a holistic portfolio around heart failure, this could be the missing element or team brings both startup spirit and corporate level experience establishing some of the fame companies stemming from Israel, while also leading innovative and approved devices in neurostimulation, in interventional and in structural heart, our Scientific Advisory Board comprises some of the true luminaries of the heart failure management space, if you're a ponikowski, who led the European guidelines in Heartfilia management and the world renowned Maria Rosa Constanza. Oregon is raised to data more than $6 million mostly from non dilutive sources, including the horizon 2020 to significantly de risk the program to reach the first in human trials that is currently ongoing with a gen one system. This will be followed with the gen two miniaturized system, initially for the Heartfilia market later on pursue growth opportunities in the renal indication, which also sets a very attractive market with strong need for out of hospital integrated care. So I'll be happy to talk about partnership opportunities, please do reach out to me in the conference or Iran. Thank you so much.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
